Amgen
AMGN
$348.62
+0.78%
Amgen Inc. is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering innovative human therapeutics across a broad range of serious illnesses, including oncology, cardiovascular disease, bone health, neuroscience, and inflammation. The company is a dominant, established player in the biopharmaceutical industry, distinguished by its deep portfolio of blockbuster drugs, a growing biosimilars business, and strategic acquisitions like Horizon Therapeutics that expanded its rare disease footprint. The current investor narrative is dominated by the significant regulatory and commercial implications of the Trump administration's proposed 100% tariffs on imported drugs, with Amgen positioned as a potential beneficiary due to its domestic manufacturing, alongside ongoing scrutiny of drug safety profiles, as evidenced by a recent FDA warning for its drug Tavneos.…
AMGN
Amgen
$348.62
Related headlines
Investment Opinion: Should I buy AMGN Today?
Rating & Thesis: Amgen is a Hold. The core thesis is that the stock offers a balanced risk/reward profile at current levels, with strong fundamentals offset by high leverage and near-term catalysts that could swing sentiment in either direction. Analyst sentiment is mixed but leans neutral, reflecting this equilibrium.
Supporting Evidence: The hold rating is supported by four key data points. First, valuation is reasonable but not deeply compelling, with a forward P/E of 15.25x implying growth but a trailing P/E of 22.84x near the lower end of its recent historical band (from 56.17x). Second, revenue growth is positive and accelerating sequentially (Q4 YoY +8.91%). Third, profitability is exceptional with an 81.91% gross margin and a 20.99% net margin. Fourth, the company generates massive free cash flow ($8.1B TTM) to support its capital allocation. However, the high debt-to-equity ratio of 6.31 tempers enthusiasm.
Risks & Conditions: The two biggest risks that could invalidate the hold thesis are: 1) a worsening of the Tavneos safety profile leading to guidance cuts, and 2) an inability to de-lever the balance sheet meaningfully while maintaining the dividend. This Hold would upgrade to a Buy if the forward P/E compressed further towards 14x on sustained revenue growth, or if the company announced a accelerated debt paydown plan. It would downgrade to a Sell if quarterly revenue growth decelerated below 5% or if net debt increased significantly. Relative to its history and the growth implied by its forward multiple, the stock appears fairly valued.
Sign up to view all
AMGN 12-Month Price Forecast
The AI assessment is Neutral with Medium confidence. Amgen is a fundamentally strong company with excellent cash generation and a diversified portfolio, but its investment story is currently capped by high financial leverage and emerging drug-specific safety risks. The forward P/E suggests the market expects solid earnings growth, primarily from the Horizon integration, but the recent FDA warning introduces uncertainty. The stock is best suited for income-oriented, risk-averse investors who can tolerate slow, steady appreciation. The stance would upgrade to Bullish on evidence of sustained debt reduction and resolution of the Tavneos safety issue. It would downgrade to Bearish if quarterly revenue growth decelerates or if leverage metrics worsen.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $453.21 and implied upside of +30.0% versus the current price.
Average Target
$453.21
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$279 - $453
Analyst target range
Amgen is covered by 15 analysts, indicating strong institutional research interest. The consensus sentiment appears mixed but leans neutral-to-bullish, with recent actions including reiterations of 'Equal Weight' (Morgan Stanley, Wells Fargo), 'Overweight' (Piper Sandler), 'Buy' (UBS, Argus), and 'Neutral' (Citigroup, Cantor). One notable downgrade occurred in February 2026 when Freedom Broker moved from 'Buy' to 'Hold'. The average target price is not explicitly provided in the data, so the implied upside cannot be calculated; however, the distribution of actions suggests a range of views. The target price range is also not specified in the provided dataset. Typically, a high target would assume successful pipeline execution, sustained growth from the Horizon portfolio, and multiple expansion, while a low target would factor in competitive pressures, pipeline setbacks, or regulatory headwinds like drug pricing pressures. The recent news flow regarding tariffs and drug safety warnings likely contributes to a wider dispersion of analyst views, signaling elevated uncertainty around the stock's near-term path. The presence of multiple recent reiterations without major changes indicates analysts are in a 'wait-and-see' mode pending further fundamental data.
Bulls vs Bears: AMGN Investment Factors
The evidence for AMGN presents a balanced but nuanced picture, with a slight edge to the bullish case based on fundamental strength and valuation. The bull thesis is anchored in accelerating revenue growth, robust profitability, a compelling forward P/E of 15.25x, and potential tailwinds from domestic drug manufacturing tariffs. The bear case highlights significant financial leverage (D/E of 6.31), earnings volatility from acquisition-related charges, and emerging regulatory risks like the FDA warning for Tavneos. The single most important tension in the investment debate is whether the company's strong free cash flow and growth from newer products can sustainably service its high debt and overcome pipeline-specific safety concerns, thereby validating its discounted forward multiple. The resolution of the tariff policy and Tavneos safety profile will be critical near-term catalysts.
Bullish
- Strong Revenue Acceleration: Quarterly revenue for 2025 grew sequentially from $8.149B in Q1 to $9.896B in Q4, demonstrating accelerating commercial momentum. This 8.91% year-over-year growth in Q4 is driven by a diversified portfolio, with Prolia ($1.054B), Otezla ($625M), and Tepezza ($457M) as key contributors.
- Attractive Valuation on Growth: The stock trades at a forward P/E of 15.25x, a significant discount to its trailing P/E of 22.84x, implying strong expected earnings growth. The PEG ratio of 0.26 suggests the stock is deeply undervalued relative to its historical earnings growth rate.
- Robust Profitability & Cash Flow: Amgen maintains an exceptionally high gross margin of 81.91% (Q4 2025) and generates substantial free cash flow ($8.1B TTM). This strong cash generation supports its dividend (payout ratio 66.45%) and provides financial flexibility despite elevated leverage.
- Potential Tariff Beneficiary: Recent news highlights the Trump administration's proposed 100% tariffs on imported drugs. Amgen's significant domestic manufacturing footprint positions it as a potential beneficiary, creating a competitive moat against import-dependent peers.
Bearish
- Elevated Debt Burden: The debt-to-equity ratio of 6.31 reflects significant leverage used to finance the Horizon acquisition. While cash flow is strong, this high debt load increases financial risk and interest expense, which was $653M in Q4 2025.
- Earnings Volatility & One-Time Charges: Q4 2025 net income of $1.333B represented a sharp sequential decline from Q3's $3.216B, largely due to a $2.428B 'total other income expenses net' charge. This volatility complicates earnings predictability and highlights integration/restructuring costs.
- Regulatory & Safety Headwinds: The FDA recently issued a warning about fatal liver risks linked to Amgen's drug Tavneos. This introduces significant commercial and regulatory risk for a key rare disease asset acquired via Horizon, potentially impacting future growth expectations.
- Technical Resistance & Slowing Momentum: The stock is trading at $355.30, near 80% of its 52-week range ($261.43 to $391.29), indicating it is approaching key resistance. Momentum has slowed, with the stock up only 1.09% over the past month, lagging the SPY's 7.36% gain.
AMGN Technical Analysis
The stock is in a sustained uptrend over the past year, having gained 28.133% and currently trading at $355.30, which is approximately 80% of its 52-week range ($261.43 to $391.29). This positioning near the upper end of the range suggests strong momentum but also indicates the stock is approaching a key technical resistance level, which could lead to consolidation. Recent momentum shows a deceleration from the powerful longer-term trend, with the stock up only 1.0868% over the past month and 7.5331% over the past three months, lagging the broader market's 7.36% and 2.67% gains over the same periods, respectively. This divergence suggests the stock is undergoing a period of digestion and relative underperformance after its significant run-up earlier in the year. Key technical support is anchored at the 52-week low of $261.43, while immediate overhead resistance sits at the 52-week high of $391.29. A decisive breakout above $391.29 would signal a resumption of the primary bull trend and likely target new all-time highs, whereas a breakdown below recent support near $340 could signal a deeper correction. The stock exhibits low market-relative volatility, with a beta of 0.465, meaning it is approximately 53.5% less volatile than the SPY; this defensive characteristic is typical for large-cap healthcare stocks and implies smaller daily price swings, which can influence position sizing for risk-averse investors.
Beta
0.47
0.47x market volatility
Max Drawdown
-17.0%
Largest decline past year
52-Week Range
$261-$391
Price range past year
Annual Return
+25.4%
Cumulative gain past year
| Period | AMGN Return | S&P 500 |
|---|---|---|
| 1m | +0.1% | +8.5% |
| 3m | +1.1% | +2.8% |
| 6m | +19.5% | +4.6% |
| 1y | +25.4% | +32.3% |
| ytd | +6.4% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMGN Fundamental Analysis
Amgen's revenue trajectory is positive but exhibits quarterly volatility, with Q4 2025 revenue of $9.896 billion representing a solid 8.91% year-over-year growth. However, examining the sequential quarterly revenue for 2025—$8.149B, $9.167B, $9.557B, $9.896B—reveals a clear pattern of accelerating growth throughout the year, suggesting strong commercial execution and contribution from newer products. Segment data highlights key growth drivers, with Prolia leading at $1.054 billion, followed by Otezla ($625M) and the recently acquired Tepezza ($457M), indicating a diversified portfolio beyond legacy products like Enbrel ($532M). The company is consistently profitable, posting net income of $1.333 billion in Q4 2025, though this represents a significant sequential decline from Q3's $3.216 billion, largely due to a $2.428 billion 'total other income expenses net' charge in Q4. Gross margin remains exceptionally robust at 81.91% for the quarter, consistent with its biotech peer group, and the trailing twelve-month net margin is a healthy 20.99%. Profitability metrics are strong, with a return on equity of 89.06%, though this is inflated by a high debt load, and a return on assets of 7.93%. Amgen's balance sheet is leveraged, with a debt-to-equity ratio of 6.31, reflecting the financing used for the Horizon acquisition. Despite this, liquidity is adequate with a current ratio of 1.14. The company generates substantial cash, with trailing twelve-month free cash flow of $8.1 billion, providing ample internal funding for dividends (payout ratio 66.45%), debt service, and business development. The strong free cash flow yield supports the company's financial flexibility despite its elevated leverage.
Quarterly Revenue
$9.9B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.81%
Latest Quarter
Free Cash Flow
$8.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMGN Overvalued?
Given Amgen's consistent profitability (Net Income > 0), the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 22.84x and a forward PE of 15.25x based on analyst estimates. The significant discount of the forward multiple implies the market expects substantial earnings growth in the coming year, likely driven by the full integration of Horizon's assets and continued growth of newer launches. Compared to sector averages, Amgen's trailing PE of 22.84x appears to be at a premium; however, specific industry average data is not provided in the valuation dataset for a direct comparison. Its Price-to-Sales ratio of 4.79x and EV/EBITDA of 13.99x are more standard metrics for a large-cap biopharma. The stock's PEG ratio of 0.26, based on trailing figures, suggests it is deeply undervalued relative to its growth rate, though this metric can be volatile and sensitive to earnings timing. Historically, Amgen's current trailing PE of 22.84x sits well below its own recent peaks, such as 56.17x at the end of 2024 and 33.09x at the end of Q4 2025. This compression towards the lower end of its recent historical band suggests the market has de-risked the shares following the Horizon acquisition and amidst macro uncertainties, potentially offering a more attractive entry point if the growth thesis holds.
PE
22.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -336x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Amgen's primary financial risk stems from its elevated leverage, with a debt-to-equity ratio of 6.31 following the Horizon Therapeutics acquisition. While annual free cash flow of $8.1 billion provides coverage, a significant portion is allocated to dividends (payout ratio 66.45%), leaving less flexibility for debt reduction. Earnings volatility is another concern, as evidenced by the Q4 2025 net income of $1.333B being 59% lower than Q3, largely due to a $2.428B non-operating charge. Furthermore, revenue, while growing, remains exposed to patent expiries and drug-specific safety issues, as seen with the recent FDA warning for Tavneos, a key Horizon asset that generated $457M in Q4.
Market & Competitive Risks: Valuation compression is a key market risk; although the forward P/E of 15.25x appears reasonable, the stock trades near the upper end of its 52-week range, 80% towards its high of $391.29, leaving limited near-term multiple expansion room. The stock's low beta of 0.465 suggests defensive characteristics but also implies it may lag in strong bull markets, as seen in its 1-month underperformance versus the SPY (-6.27% relative strength). Competitive and regulatory risks are heightened, with the proposed 100% drug tariffs creating a bifurcated landscape and ongoing political scrutiny of drug pricing. The recent Tavneos safety warning could lead to prescribing restrictions or label changes, directly impacting a growth driver.
Worst-Case Scenario: The most damaging scenario would involve a combination of the Tavneos safety issue escalating into a severe label restriction or withdrawal, coupled with a macroeconomic downturn that pressures healthcare budgets and compresses valuation multiples across the sector. This could be exacerbated if interest rates remain elevated, increasing the cost of servicing its substantial debt. In this adverse scenario, the stock could realistically re-test its 52-week low of $261.43, representing a potential downside of approximately -26% from the current price of $355.30. A drawdown of this magnitude is within historical bounds, given the stock's maximum drawdown over the period was -17.69%.
FAQ
The key risks of holding AMGN fall into three categories, ranked by severity: 1) Financial Risk: Elevated leverage with a debt-to-equity ratio of 6.31, which increases interest expense ($653M in Q4) and reduces financial flexibility. 2) Regulatory/Product Risk: The recent FDA warning about fatal liver risks linked to Tavneos, a key growth drug generating $457M quarterly, which could impact future sales and trigger further scrutiny. 3) Integration/Execution Risk: The challenge of fully integrating Horizon Therapeutics to realize expected synergies without further earnings volatility, as seen in the large Q4 2025 non-operating charge. 4) Valuation/Macro Risk: The stock trading near 52-week highs leaves limited room for multiple expansion, and its low beta means it may underperform in strong bull markets.
The 12-month forecast for AMGN is a range-bound outcome with a skew to moderate upside, based on a probabilistic assessment. The Base Case (55% probability) sees the stock trading between $355 and $390, as steady execution and cash flow support the current valuation. The Bull Case (30% probability) targets $391 to $420, driven by successful Horizon integration, resolved safety concerns, and tariff benefits. The Bear Case (15% probability) warns of a drop to the $261-$340 range if the Tavneos issue escalates or debt concerns mount. The most likely scenario is the Base Case, predicated on the assumption that the company's strong fundamentals counterbalance its known risks without significant new negative developments.
AMGN appears fairly valued relative to its near-term prospects. Its trailing P/E of 22.84x has compressed significantly from recent highs above 56x, suggesting much of the acquisition-related risk is priced in. The more relevant forward P/E of 15.25x implies the market expects solid earnings growth, which seems justified given the 8.91% YoY revenue growth in Q4 2025. The PEG ratio of 0.26 signals deep undervaluation on a growth-adjusted basis, but this metric can be volatile. Compared to its own history, the stock is at the lower end of its valuation band, but given the increased leverage and integration risks, the current multiple represents a fair price for its cash flow and growth trajectory.
AMGN is a good stock for certain investor profiles, but not a clear-cut buy for all. For income-focused, risk-averse investors seeking defensive exposure to healthcare, its ~3% dividend yield, strong cash flow, and low volatility (beta 0.465) are attractive. The forward P/E of 15.25x is reasonable for its growth profile. However, the high debt load (D/E of 6.31) and recent drug safety concerns (FDA warning for Tavneos) introduce significant risks. It is a good buy for long-term holders who believe management can successfully de-lever and navigate the regulatory landscape, but less suitable for those seeking high short-term capital appreciation.
AMGN is unequivocally more suitable for a long-term investment horizon (3-5 years minimum). Its value proposition is built on durable cash flows, a dividend that consumes two-thirds of earnings, and the long commercial cycles of biologic drugs. The low beta of 0.465 indicates low short-term trading volatility, making it less ideal for tactical swings. Furthermore, the company's strategy to pay down debt and integrate Horizon is a multi-year process. Short-term investors would be betting on specific binary events like FDA decisions or tariff news, which introduces higher risk. For building a resilient portfolio core with income, AMGN is a long-term holding.